By January 2021, just over a year after the virus was first identified, there were over 100 million cases of COVID-19 reported worldwide and several viral variants in circulation. The unprecedented nature of the pandemic has magnified the need for accelerated scientific discoveries as researchers strive to bring novel therapeutics, vaccines and diagnostic solutions to market.
One of the core tenets of viral research lies in understanding how the virus interacts with biological targets and protective antibodies, and access to reliable, sensitive and automated technology is paramount to our progress.
During this session, we’ll discuss how surface plasmon resonance (SPR) has been widely adopted for label-free biomolecular characterization, and demonstrate the application of this powerful technique with a study on developing a novel COVID-19 diagnostic assay.
You’ll Learn About
Versatility & Flexibility: How the robustness and sensitivity of SPR makes it ideal for a wide range of biomolecular applications
Comprehensive Workflows: The benefits of SPR-based characterization studies for accelerating lead time on novel COVID-19 solutions
Maximizing Performance: How to develop a highly selective and specific antibody pair with SPR to optimize COVID-19 antigen detection
Looking Ahead: The next generation of SPR platforms advancing label-free detection to address the unmet needs of infectious disease research
The information and opinions provided by speakers as well as Sino Biological employees during hosted webinar series are solely of their own and Sino Biological assumes no responsibility or liability for this content.
About Sino Biological
Sino Biological specializes in antibody development and recombinant protein production. All of Sino Biological’s products are independently developed and produced. Sino Biological offers pharmaceutical companies and biotechnology firms a variety of recombinant production and assay services for pre-clinical research development work. Sino Biological is dedicated to virology and infectious disease research. Its ProVirTM collection is the world’s largest viral antigen bank, carrying over 800 products from 350 strains of viruses. Sino Biological is the first company in the world to produce and supply the SARS-CoV-2 viral protein reagents. To support the development of immunodiagnostic assay, Sino Biological has developed a comprehensive collection of antigens and antibodies for SARS-CoV-2.
Nicoya is a Canadian biotechnology company whose mission is to improve human life by helping scientists succeed. The company develops innovative and accessible SPR platforms for rapid, reliable, and label-free characterization of biomolecules, including antibodies. Nicoya’s SPR platforms help biotechnology and pharmaceutical companies bring their latest discoveries to market faster. Currently, Nicoya is empowering 600+ scientists worldwide to push the limits of discovery.